Datopotamab–deruxtecan (Dato-DXd)—an ADC targeting TROP2, with the same cytotoxic payload as T-DXd, showed an ORR of 29% and a DCR of 85% in a heavily pretreated HR + /HER2− ABC population (median 5 prior lines of treatment) in the phase I TROPION-PanTumor01 trial113. Here, HR is linked to aneurysmal bone cyst.